A month after brokering a new Phase III trial of Chimerix's investigational antiviral drug, company CEO Kenneth I. Moch has been replaced and will be pursuing other interests. The company announced ...
Just weeks after enduring a storm of controversy triggered by his initial refusal to provide a potent but experimental antiviral to a dying child under a compassionate use program, Chimerix CEO Ken ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback